Phosphorylation of syndecan-4 regulates myocardial hypertrophy through the calcineurin-NFAT signalling pathway

Ida G. Lunde1,2, Alexandra V. Finsen1,2,3, Even K. Østli4, Marianne Lyngra1,2, Ivar Sjaastad1,2,5, Hilde O. Jarstadmarken1,2, Almira Hasic1,2, Ståle Nygård1,2,6, Sarah A. Wilcox-Adelman7, Paul F. Goetinck8, Torstein Lyberg9, Theis Tønnessen2,10, Srdjan Djurovic4, Cathrine R. Carlson1,2, Geir Christensen1,2

1 Institute for Experimental Medical Research, Oslo University Hospital Ullevål, Oslo, Norway.
2 Center for Heart Failure Research, University of Oslo, Oslo, Norway.
3 Research Institute for Internal Medicine and Department of Cardiology, Rikshospitalet University Hospital, Oslo, Norway.
4 Department of Medical Genetics, Oslo University Hospital, Oslo, Norway.
5 Department of Cardiology, Oslo University Hospital, Oslo, Norway.
6 Department of Mathematics, University of Oslo, Oslo, Norway.
7 Boston Biomedical Research Institute, Watertown, Massachusetts, USA.
8 Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA.
9 Center for Clinical Research, Ullevaal Oslo Hospital, Oslo, Norway.
10 Department of Cardiothoracic Surgery, Oslo University Hospital, Oslo, Norway.

Myocardial hypertrophy and subsequent heart failure develop in response to pressure overload, however the signalling processes involved are poorly understood. We here demonstrate a crucial role for phosphorylation of syndecan-4, a transmembrane proteoglycan localized to costameres and Z-discs in cardiomyocytes, in regulating the calcineurin-Nuclear Factor of Activated T-cell (NFAT) signalling which is involved in development of concentric hypertrophy. More specifically, we have investigated the interaction between syndecan-4 and the calcineurin-NFAT signalling pathway in a pressure-overload aorta-banding model of cardiac hypertrophy in mice.

In vitro results showed that recombinant calcineurin was pulled down with syndecan-4 and to a lesser extent with syndecan-2. The association between endogenous calcineurin, its activator calmodulin and syndecan-4 was increased in left ventricular lysates isolated from pressure-overloaded hearts compared to sham-operated controls. The cytoplasmic part of syndecan-4 is 28 amino acids long and composed of three regions, C1, V and C2. C1 and C2 are conserved between the four syndecans, while the V-region is specific for each of them. In vitro pull-down and peptide array experiments showed that calcineurin interacts with the V-region of syndecan-4 through its auto inhibitory domain. Previous results have shown that phosphorylation of serine 179 (S179) is important for PKCα-binding and activation. We here show that the level of phosphorylation of S179 was reduced in pressure-overloaded hearts compared to sham controls and that more calcineurin was immunoprecipitated and pulled-down with non-phosphorylated syndecan-4 than with the phosphorylated version.

In summary, in a pressure-overloaded heart, serine 179 in syndecan-4 is dephosphorylated and calcineurin binds to the intracellular V-region through its auto inhibitory domain. Binding of calcineurin to syndecan-4 results in increased activation of NFATc4, a well-known pro-hypertrophic transcription factor. Conclusively, these data indicate a crucial role for the syndecan-4-calcineurin interaction in development of concentric hypertrophy.